摘要Dear Editor,Thyroid-associated ophthalmopathy(TAO),or Graves' ophthalmopathy(GO),is a complex autoimmune condition characterized by eye symptoms such as proptosis,lid retraction,and periorbital swelling,often associated with thyroid dysfunction[1].Current drug treatments primarily include glucocorticoids,traditional immunosuppressants,and novel biologics such as Teprotumumab.While able to alleviate symptoms,they often do not adequately address irreversible conditions such as visual impairment and fibrosis,and it is difficult to avoid long-term medication side effects.In this context,exploring new therapeutic avenues for TAO to improve patients' prognosis and quality of life is meaningful.We proposed chimeric antigen receptor(CAR)-based therapy as a novel treatment orientation.